Related references
Note: Only part of the references are listed.Measurement of specific organ domains in lupus randomized controlled trials: a scoping review
Kathryn Connelly et al.
RHEUMATOLOGY (2022)
The ALPHA Project: Establishing consensus and prioritisation of global community recommendations to address major challenges in lupus diagnosis, care, treatment and research
Karin Tse et al.
LUPUS SCIENCE & MEDICINE (2021)
Response to placebo in non-renal, non-neuropsychiatric systemic lupus erythematosus: a systematic review and pooled analysis
Konstantinos Tselios et al.
RHEUMATOLOGY (2021)
Trial of Anifrolumab in Active Systemic Lupus Erythematosus
Eric F. Morand et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Attainment of treat-to-target endpoints in SLE patients with high disease activity in the atacicept phase 2b ADDRESS II study
Eric F. Morand et al.
RHEUMATOLOGY (2020)
Use of Physician Global Assessment in systemic lupus erythematosus: a systematic review of its psychometric properties
Elisabetta Chessa et al.
RHEUMATOLOGY (2020)
Lupus Low Disease Activity State (LLDAS) discriminates responders in the BLISS-52 and BLISS-76 phase III trials of belimumab in systemic lupus erythematosus
Shereen Oon et al.
ANNALS OF THE RHEUMATIC DISEASES (2019)
Development of the Asia Pacific Lupus Collaboration cohort
Rangi Kandane-Rathnayake et al.
INTERNATIONAL JOURNAL OF RHEUMATIC DISEASES (2019)
Global consensus building and prioritisation of fundamental lupus challenges: the ALPHA project
Susan Manzi et al.
LUPUS SCIENCE & MEDICINE (2019)
Type I interferon inhibitor anifrolumab in active systemic lupus erythematosus (TULIP-1) a randomised, controlled, phase 3 trial
Richard A. Furie et al.
LANCET RHEUMATOLOGY (2019)
Clinical trial parameters that influence outcomes in lupus trials that use the systemic lupus erythematosus responder index
Kenneth C. Kalunian et al.
RHEUMATOLOGY (2018)
Lupus Low Disease Activity State (LLDAS) attainment discriminates responders in a systemic lupus erythematosus trial: post-hoc analysis of the Phase IIb MUSE trial of anifrolumab
Eric F. Morand et al.
ANNALS OF THE RHEUMATIC DISEASES (2018)
Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 2 trial
Daniel J. Wallace et al.
LANCET (2018)
Systemic Lupus Erythematosus (SLE) Responder Index response is associated with global benefit for patients with SLE
R. Furie et al.
LUPUS (2018)
Phase III trial results with blisibimod, a selective inhibitor of B-cell activating factor, in subjects with systemic lupus erythematosus (SLE): results from a randomised, double-blind, placebo-controlled trial
Joan T. Merrill et al.
ANNALS OF THE RHEUMATIC DISEASES (2018)
Efficacy and safety of ustekinumab, an IL-12 and IL-23 inhibitor, in patients with active systemic lupus erythematosus: results of a multicentre, double-blind, phase 2, randomised, controlled study
Ronald F. van Vollenhoven et al.
LANCET (2018)
Clinical response beyond the Systemic Lupus Erythematosus Responder Index: post-hoc analysis of the BLISS-SC study
Ronald F. van Vollenhoven et al.
LUPUS SCIENCE & MEDICINE (2018)
Lupus community panel proposals for optimising clinical trials: 2018
Joan T. Merrill et al.
LUPUS SCIENCE & MEDICINE (2018)
A framework for remission in SLE: consensus findings from a large international task force on definitions of remission in SLE (DORIS)
Ronald van Vollenhoven et al.
ANNALS OF THE RHEUMATIC DISEASES (2017)
Clinician-Reported Outcome Assessments of Treatment Benefit: Report of the ISPOR Clinical Outcome Assessment Emerging Good Practices Task Force
John H. Powers et al.
VALUE IN HEALTH (2017)
Efficacy and Safety of Epratuzumab in Moderately to Severely Active Systemic Lupus Erythematosus Results From Two Phase III Randomized, Double-Blind, Placebo-Controlled Trials
Megan E. B. Clowse et al.
ARTHRITIS & RHEUMATOLOGY (2017)
Efficacy and safety of subcutaneous tabalumab, a monoclonal antibody to B-cell activating factor, in patients with systemic lupus erythematosus: results from ILLUMINATE-2, a 52-week, phase III, multicentre, randomised, double-blind, placebo-controlled study
J. T. Merrill et al.
ANNALS OF THE RHEUMATIC DISEASES (2016)
Definition and initial validation of a Lupus Low Disease Activity State (LLDAS)
Kate Franklyn et al.
ANNALS OF THE RHEUMATIC DISEASES (2016)
Efficacy and safety of subcutaneous tabalumab in patients with systemic lupus erythematosus: results from ILLUMINATE-1, a 52-week, phase III, multicentre, randomised, double-blind, placebo-controlled study
D. A. Isenberg et al.
ANNALS OF THE RHEUMATIC DISEASES (2016)
Clinical, laboratory and health-related quality of life correlates of Systemic Lupus Erythematosus Responder Index response: a post hoc analysis of the phase 3 belimumab trials
Richard Furie et al.
LUPUS SCIENCE & MEDICINE (2014)
Derivation and validation of the systemic lupus international collaborating clinics classification criteria for systemic lupus erythematosus
Michelle Petri et al.
ARTHRITIS AND RHEUMATISM (2012)
A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus
Richard Furie et al.
ARTHRITIS AND RHEUMATISM (2011)
Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial
Sandra V. Navarra et al.
LANCET (2011)
Novel Evidence-Based Systemic Lupus Erythematosus Responder Index
Richard A. Furie et al.
ARTHRITIS & RHEUMATISM-ARTHRITIS CARE & RESEARCH (2009)
Share Paper
